A phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 given orally to patients with solid tumors.

被引：0
|
作者：
Strumberg, D
Bauer, RJ
Moeller, JG
Hilger, R
Diaz-Carballo, D
Richly, H
Kredtke, S
Beling, C
Faghih, M
Heinig, R
Hedley, D
Scheulen, ME
Seeber, S
机构：
[1] Univ Essen Gesamthsch, W German Canc Ctr, Essen, Germany
[2] Bayer AG, D-5600 Wuppertal, Germany
[3] Ontario Canc Inst, Toronto, ON M4X 1K9, Canada
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285
引用
收藏
页码：3711S / 3711S
页数：1
相关论文
共 50 条
  • [1] A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid cancers.
    Awada, A
    Hendlisz, A
    Gil, T
    Bleiberg, H
    Bartholomeus, S
    De Valeriola, D
    Dewitte, M
    Coppieters, S
    Moeller, J
    De Becker, D
    Meert, A
    Piccart, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [2] Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension.
    Veronese, ML
    Flaherty, KT
    Townsend, R
    Mosenkis, A
    Zimmer, R
    Rosen, M
    Gallagher, M
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 135S - 135S
  • [3] A clinical phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors
    Strumberg, D
    Voliotis, D
    Moeller, JG
    Hilger, RA
    Richly, H
    Beling, C
    Tewes, M
    Schleucher, N
    Scheulen, ME
    Seeber, S
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S53 - S54
  • [4] Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
    Strumberg, D
    Richly, H
    Hilger, RA
    Schleucher, N
    Korfee, S
    Tewes, M
    Faghih, M
    Brendel, E
    Voliotis, D
    Haase, CG
    Schwartz, B
    Awada, A
    Voigtmann, R
    Scheulen, ME
    Seeber, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) : 965 - 972
  • [5] Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced refractory solid tumors.
    Hirte, H
    Moore, MJ
    Oza, AM
    Siu, LL
    Harris, H
    Maclean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [6] Final results of a phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours
    Hirte, H
    Moore, M
    Hotte, S
    Oza, A
    Siu, L
    Harris, H
    MacLean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S55 - S55
  • [7] Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors
    Steinbild, S
    Baas, F
    Gmehling, D
    Brendel, E
    Christensen, O
    Schwartz, B
    Mross, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 220S - 220S
  • [8] A phase I study of BAY 43-9006, a dual inhibitor of Raf and VEGFR kinases, in Japanese patients with solid cancers.
    Minami, H
    Kawada, K
    Ebi, H
    Kitagawa, K
    Kim, YI
    Araki, K
    Mukai, H
    Tahara, M
    Nakajima, H
    Nakajima, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 207S - 207S
  • [9] Inhibition of ERK phosphorylation in patients treated with the Raf kinase inhibitor BAY 43-9006
    Hilger, RA
    Kredtke, S
    Hedley, D
    Moeller, JG
    Voliotis, D
    Stellberg, W
    Seeber, S
    Scheulen, ME
    Strumberg, D
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S52 - S53
  • [10] Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma.
    Flaherty, KT
    Redlinger, M
    Schuchter, LM
    Lathia, CD
    Weber, BL
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 201S - 201S
12345